{"id":106514,"date":"2026-07-22T10:01:03","date_gmt":"2026-07-22T10:01:03","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/106514\/"},"modified":"2026-07-22T10:01:03","modified_gmt":"2026-07-22T10:01:03","slug":"a-wild-west-how-one-swiss-company-aims-to-tame-the-botox-boom","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/106514\/","title":{"rendered":"\u2018A wild west\u2019: how one Swiss company aims to tame the botox boom"},"content":{"rendered":"

\"face<\/p>\n

Standard procedure: a botox injection to head off wrinkles around the eyes. <\/p>\n

AP <\/p>\n

Galderma, headquartered in the Swiss canton of Zug, is training thousands of doctors to administer jabs as the risk of botched procedures rises.\n<\/p>\n

Listen to the article <\/p>\n

Listening the article <\/p>\n

Toggle language selector <\/p>\n

English (US) <\/p>\n

English (British) <\/p>\n

Generated with artificial intelligence. <\/p>\n

This content was published on <\/p>\n

July 22, 2026 – 09:57\n<\/p>\n

\n Madeleine Speed in London, Mercedes Ruehl in Zurich, Financial Times <\/p>\n

Keywan Taghetchian, a Zurich-based doctor who trains practitioners on how to use Galderma\u2019s treatments, asserts that \u201cbeauty is very objective\u201d.<\/p>\n

Galderma is one of the prime beneficiaries of the normalisation of \u201ctweakments\u201d like botox and filler.<\/p>\n

Sales of its injectables \u2013 which include botulinum toxin (equivalent to US company AbbVie\u2019s Botox), gel-like \u201cfillers\u201d to add volume under the skin and injections that stimulate collagen production \u2013 rose 11.5% to $2.5bn (CHF2.02 billion) in 2025.<\/p>\n

External Content <\/p>\n

\"FT\"<\/p>\n

Clinics administering these treatments have become a fixture of high streets and shopping malls in the past few years. Doctors-turned-influencers tout new procedures on social media, posting close-up videos of people having needles inserted into their lips and foreheads. Hollywood actors appear to have stopped ageing.<\/p>\n

In an interview at Galderma\u2019s immaculate lakeside headquarters in Zug, chief executive Flemming \u00d8rnskov said \u201cthe train has left the station in terms of people wanting to look a certain way, to augment what they want to augment\u201d.<\/p>\n

For Galderma, however, this surge in demand comes with risks. The company exerts little control over who administers its treatments, potentially leaving it exposed when they go wrong. Unwanted side effects of injectables such as botox range from swelling to a crooked smile or trouble breathing.<\/p>\n

Naveen Cavale, a board member at the International Society of Aesthetic Plastic Surgery (ISAPS), said the injector industry was \u201ca wild west\u201d. The established companies did their best to stop their product getting into the wrong hands, she said, but there was only so much they could do.<\/p>\n

Galderma is now racing to train up the fast-growing ranks of doctors, dentists and nurses entering the aesthetics field and injecting its products into members of the public.<\/p>\n

\n More<\/p>\n

\"ageing<\/p>\n

More <\/p>\n

Healthcare innovation\n <\/p>\n

Longevity clinics: modern-day snake oil or the key to healthy ageing? <\/p>\n

\n

This content was published on <\/p>\n

May 2, 2025 <\/p>\n

Scientists have yet to find the elixir of life but this hasn\u2019t stopped longevity clinics from selling treatments, pills and gadgets that claim to slow ageing. <\/p>\n

<\/p>\n

Read more: Longevity clinics: modern-day snake oil or the key to healthy ageing?
\n <\/a><\/p>\n

The Swiss company was founded in 1981 as a joint venture between L\u2019Or\u00e9al and Nestl\u00e9. After five years under the ownership of a consortium led by private equity firm EQT, Galderma was floated on the Swiss stock exchange in 2024.<\/p>\n

Its shares have more than doubled since and Galderma has become the world\u2019s second-largest injectables maker after US healthcare giant AbbVie, with a market capitalisation of about CHF41 billion.<\/p>\n

The group\u2019s shares fell 6% earlier this month, however, after the US Food and Drug Administration turned down its application for the approval of Relfydess, a longer-lasting rival of Botox.<\/p>\n

As well as injectables, which make up about half of group sales, Galderma sells prescription drugs for skin conditions, such as eczema and acne, and specialist skincare brands like Cetaphil. Analysts estimate the Swiss company will generate $1.1 billion of pre-tax profit this year on revenues of $6.3 billion, which would be an increase of 21% on last year.<\/p>\n

L\u2019Or\u00e9al has reinvested with a 20% stake. The beauty company\u2019s chief executive, Nicolas Hieronimus, has said women who pay for the sort of treatments Galderma offers spend twice as much on creams and beauty products.<\/p>\n

Longevity boom<\/p>\n

The two companies are capitalising on the booming business of longevity, driven by wealthy women typically between the ages of 40 and 65.<\/p>\n

\u00d8rnskov\u00a0trained as a doctor in his native Denmark before moving into the pharmaceutical industry. He now hosts a video series, \u201cBeauty X Medicine\u201d, which \u201cuncover[s] the science behind beautiful, healthy skin\u201d, featuring guests such as Dr Jean Carruthers, who first discovered that Botox could treat frown lines. Her catchphrase: \u201cI haven\u2019t frowned since 1987.\u201d<\/p>\n

Galderma\u2019s chief said its core consumers want to \u201cage in a natural way\u201d and is keen to distance the company from the \u201cpillow face\u201d look of those who have applied fillers liberally.<\/p>\n

Galderma and AbbVie suffered a slowdown in sales a few years ago following a period of \u201cfiller fatigue\u201d. \u00d8rnskov said the company dealt with the slowdown by pushing Sculptra, an injection that helps stimulate collagen production.<\/p>\n

It was first used to treat people living with HIV\/Aids who lost fat around their cheeks and temples. Now it is a hit with users of GLP-1 drugs such as Ozempic and Wegovy who experience the same conditions from rapid weight loss.<\/p>\n

\n More<\/p>\n

\"billboard<\/p>\n

More <\/p>\n

Healthcare innovation\n <\/p>\n

Pharma\u2019s obesity campaigns juggle awareness and advertising <\/p>\n

\n

This content was published on <\/p>\n

Jun 4, 2026 <\/p>\n

Pharma giants are bankrolling obesity awareness campaigns, raising thorny questions about what constitutes drug advertising. <\/p>\n

<\/p>\n

Read more: Pharma\u2019s obesity campaigns juggle awareness and advertising
\n <\/a><\/p>\n

\u00d8rnskov\u2019s contention that Galderma\u2019s products give users a \u201cnatural look\u201d is dependent on them being administered judiciously by trained professionals.<\/p>\n

The ballooning number of clinics and medical spas offering injectables has drawn large numbers of untrained providers into the industry, raising the risk of botched procedures.<\/p>\n

UK and US expansion<\/p>\n

A University College London study published earlier this year counted 19,701 professionals administering botox in the UK in 2025, a jump of 437% in just two years. Doctors made up 28% of all practitioners, while the proportion of aestheticians injecting botox without a medical licence doubled to 24%.<\/p>\n

Parts of the US show a similar pattern. A study last year by the University of Central Florida and the American Foundation for Aesthetic Medicine found that the number of medical spas in Florida doubled over a four-year period to 1,038. Over three quarters of them were found to be run by practitioners with no training in aesthetic medicine.<\/p>\n

Rules governing who is allowed to inject Galderma\u2019s products vary. In the UK, practitioners do not need dedicated training to inject fillers, so long as they are a medical professional. Rules vary state by state in the US. Galderma says that, where possible, it only sells to qualified injectors.<\/p>\n

The company said it wants to train as many practitioners buying its products as possible. In 2025, Galderma trained more than 100,000 healthcare professionals.<\/p>\n

Stefan Schneider, analyst at Vontobel, said \u201cthe goal is to minimise the risk of adverse outcomes that could end up associated with the brand through social media\u201d.<\/p>\n

\u201cThese programmes are expensive and time-consuming, but they\u2019re essential,\u201d he added.<\/p>\n

Galderma was raided by French authorities in April on suspicion that two of its Botox-like brands were illegally sold to general practitioners. The country\u2019s rules state that botox must be administered by doctors with specialities in dermatology or cosmetics<\/p>\n

\u00d8rnskov said it was difficult to control where products ended up in France because they had to be sold through pharmacies. \u201cFrance is a special situation,\u201d he said. \u201cWe will do everything possible. We have stopped delivering to certain pharmacies.\u201d<\/p>\n

\u2018Baby botox\u2019 for prevention<\/p>\n

Another area of concern to regulators is a growing trend for so-called \u201cbaby botox\u201d, in which young people procure the injections as a preventive measure, in the hope it will stop wrinkles ever forming.<\/p>\n

Barclays analyst James Gordon said anecdotal evidence from clinicians showed growing use of botox among women in their twenties was helping drive overall injectables growth.<\/p>\n

\u201cWhen you\u2019ve got people who might start a lot younger, then they potentially stay on [the jabs] for their entire life,\u201d he said.\u00a0<\/p>\n

A report by the UK government\u2019s Women and Equalities Commission found that higher demand for cosmetic procedures, particularly among young women, has in recent years been driven in part by extensive use of social media, where practitioners advertise their services.<\/p>\n

\u00d8rnskov pushed back on concerns about Galderma\u2019s role in driving this trend, arguing that the scale of its business was \u201ca drop in the ocean\u201d compared with the global cosmetics industry, as well as sectors like nutrition and wellness.<\/p>\n

\u201cWe are such a small part of a colossal, monumental wave in society where people want to live longer, look better,\u201d he said.<\/p>\n

\u201cAnd of course, the thing they look at every single day is the face.\u201d<\/p>\n

Copyright The Financial Times Limited 2026<\/p>\n

Articles in this story <\/p>\n","protected":false},"excerpt":{"rendered":"Standard procedure: a botox injection to head off wrinkles around the eyes. AP Galderma, headquartered in the Swiss…\n","protected":false},"author":2,"featured_media":106515,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[4],"tags":[101,595,18520,1990,52092,41,17,21740,21313],"class_list":["post-106514","post","type-post","status-publish","format-standard","has-post-thumbnail","category-switzerland","tag-article","tag-beat-new-treatments","tag-beat-patient-safety","tag-business-general","tag-medical-procedure-test","tag-swiss","tag-switzerland","tag-user-need-explain-it-to-me","tag-user-need-update-me"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116963055092804467","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/106514","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=106514"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/106514\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/106515"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=106514"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=106514"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=106514"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}